Frete grtis acima de 250.
Were here to assist with expert, personalized data
The Glucagon-like Peptide 1 (GLP-1) analogues market focuses on medications that mimic the effects of the natural GLP-1 hormone, which regulates blood sugar levels, insulin secretion, and appetite
Coverage for weight-loss indications remains limited under current federal law, although policy discussions continue regarding potential future expansion
Published clinical guidelines from organizations including the American Society of Metabolic and Bariatric Surgery and the Obesity Medicine Association have identified GLP-1 receptor agonists as appropriate pharmacological interventions in patients with a BMI of 30 or above (classified as obesity), or BMI of 27 or above with at least one weight-related comorbidity such as type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea - the same criteria framework used by the FDA in evaluating GLP-1 medications for their obesity management indications
In Mar 2024, Aurisco Pharmaceutical invested in cGMP peptide manufacturing capacity at its USFDA-inspected location in Yangzhou, China